• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Canada·Healthcare·CXXI.CN
Share

C21 Investments Inc. Stocks

CA$ 0.39Last Updated 21.08.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

CA$ 32.32M

CA$ 0.39
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

C21 Investments Inc. operates as a comprehensive enterprise within the cannabis sector, handling the cultivation, processing, distribution, and retail of consumer goods derived from cannabis and hemp throughout the United States. Its diverse product lineup includes both pre-packaged and bulk cannabis flower, vaporizer cartridges, concentrated extracts, edible products, pre-rolled joints, liquid tinctures, and topical applications. In addition, the company provides payroll administration and employee benefits solutions. Originally incorporated in 1987, the firm rebranded to C21 Investments Inc. in November 2017, having previously operated under the name Curlew Lake Resources Inc. Its primary corporate headquarters are situated in Vancouver, Canada.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is neutral on EV/EBITDA, reasonably pr

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.10.2026 00:18

"If the bubble bursts, it will all start with debt": How the problems of the neo-claws threaten the S&P 500

26.10.2026 23:40

Buyers of the foldable iPhone have complained about screen damage. How does this affect the stock price?

26.10.2026 23:02

One of Wall Street’s biggest bulls drops overweight call on stocks ahead of midterms

26.10.2026 22:15

Revolut has begun offering consumer loans in the U.K. What does this mean for the company?

26.10.2026 21:31

Tesla shares surged: Barclays advised buying them ahead of the merger with SpaceX

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026